Vitality Watch

Dossier clinicaltrials trial early 29-sep-2026
Small or early-phase human trial or pilot study

Vibegron for ENergy Thinking and Resilience in Aging

Key claim: A 12-week randomized, double-blind, placebo-controlled trial will test whether vibegron (GEMTESA) improves energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.

Abstract

This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.

Why this matters

Vibegron is an already-approved overactive-bladder drug being repositioned into the longevity space via a trial that measures energy metabolism, cardiometabolic risk, and physical and cognitive function — endpoints normally associated with GLP-1s or exercise mimetics. It is the second β3-adrenergic agonist (after mirabegron) to be formally probed for aging-adjacent outcomes, testing whether brown-fat activation translates into measurable healthspan signals in humans. Until readout, this is a trial launch, not a result.

Source

Link

Briefing card

Vibegron for ENergy Thinking and Resilience in Aging
Stage: trial early · clinicaltrials · 29-sep-2026

If you take vibegron (GEMTESA) for overactive bladder, a new 12-week RCT will measure whether it also shifts energy metabolism, cardiometabolic markers, and physical and cognitive function — results are not yet available.

A 12-week randomized, double-blind, placebo-controlled trial will test whether vibegron (GEMTESA) improves energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT06987383

build build 880 · 2bcef25 · 2026-11-18